Novartis On Its ‘US First’ Commercial Plan

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

US Innovative Medicines president Victor Bulto talked to Scrip about why the company is pivoting to a commercial strategy that prioritizes the US and what that means for developing and selling drugs.

upside down
Novartis is turning its commercial strategy on its head • Source: Shutterstock

Novartis AG has unveiled a new business strategy that prioritizes the US market over other geographies, a decision that will impact everything from the way the company develops drugs to the way it sells them. US Innovative Medicines president Victor Bulto is leading the "US first" effort and talked to Scrip at the J.P. Morgan Healthcare Conference about the company's ambitious new plan and commercial structure.

As Bulto describes it, the new strategy was born out of Novartis's decision last year to spin off the generic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains